Lazertinib

Overview

Lazertinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4558324).

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Lazertinib expires 1 Aug 2041 and exclusivity 19 Aug 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

Canonical SMILES

CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC

InChIKey

RRMJMHOQSALEJJ-UHFFFAOYSA-N